Payment overview · 2025
General Payments
$452.28
22 reported records · 11 companies
Healthcare provider profile · identity verified
Shelley M Gilbert, RPA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · MYRTLE BEACH, SC · NPI 1467698621
Verified facts
What the public records show
CMS Open Payments records show Shelley M Gilbert, RPA-C received $452.28 in general payments during 2025 across 22 reported records.
Lilly USA, LLC accounted for 15.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.12 | 15.5% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $58.24 | 12.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.46 | 11.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $48.59 | 10.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $47.85 | 10.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.52 | 10.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.22 | 7.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.71 | 6.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.50 | 5.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.82 | 4.8% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $18.25 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $452.28 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $70.12 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $58.24 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.46 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $52.46 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $48.59 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $47.85 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.22 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.22 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.97 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.97 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 105 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
105 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
99 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 457 | 156 |
| Alprazolam | Alprazolam | 366 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 365 | 145 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 364 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 339 | 131 |
| Lisinopril | Lisinopril | 329 | 125 |
| Metformin Hcl | Metformin Hcl | 252 | 103 |
| Azithromycin | Azithromycin | 217 | 174 |
| Zolpidem Tartrate | Zolpidem Tartrate | 208 | 42 |
| Omeprazole | Omeprazole | 198 | 71 |
| Gabapentin | Gabapentin | 185 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 176 | 68 |
| Methylprednisolone | Methylprednisolone | 168 | 146 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 64 |
| Losartan Potassium | Losartan Potassium | 165 | 72 |
| Trazodone Hcl | Trazodone Hcl | 165 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 60 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 130 | 111 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 59 |
| Simvastatin | Simvastatin | 128 | 53 |
| Furosemide | Furosemide | 126 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 36 |
| Meloxicam | Meloxicam | 125 | 54 |
| Allopurinol | Allopurinol | 122 | 48 |
| Valsartan | Valsartan | 122 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 42 |
| Montelukast Sodium | Montelukast Sodium | 119 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 105 | 29 |
| Mounjaro | Tirzepatide | 99 | 27 |
| Ozempic | Semaglutide | 97 | 27 |
| Bupropion Xl | Bupropion Hcl | 96 | 36 |
| Carvedilol | Carvedilol | 94 | 39 |
| Tramadol Hcl | Tramadol Hcl | 86 | 29 |
| Celecoxib | Celecoxib | 83 | 26 |
| Lorazepam | Lorazepam | 82 | 27 |
| Sertraline Hcl | Sertraline Hcl | 82 | 36 |
| Prednisone | Prednisone | 79 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 34 |
| Ezetimibe | Ezetimibe | 75 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 74 | 34 |
| Cephalexin | Cephalexin | 69 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 28 |
| Fenofibrate | Fenofibrate | 67 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 67 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 30 |
| Glipizide | Glipizide | 66 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 48 |
| Amoxicillin | Amoxicillin | 65 | 48 |
| Fluconazole | Fluconazole | 64 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 18 |
| Jardiance | Empagliflozin | 62 | 22 |
| Eliquis | Apixaban | 61 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 22 |
| Ondansetron Odt | Ondansetron | 59 | 40 |
| Famotidine | Famotidine | 58 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 37 |
| Paxlovid | Nirmatrelvir/Ritonavir | 54 | 53 |
| Pregabalin | Pregabalin | 54 | 22 |
| Alendronate Sodium | Alendronate Sodium | 53 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | 11 |
| Eszopiclone | Eszopiclone | 52 | 14 |
| Temazepam | Temazepam | 50 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 13 |
| Ibuprofen | Ibuprofen | 48 | 27 |
| Clonazepam | Clonazepam | 46 | 14 |
| Potassium Chloride | Potassium Chloride | 46 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 36 |
| Metformin Hcl Er | Metformin Hcl | 42 | 15 |
| Meclizine Hcl | Meclizine Hcl | 41 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Mupirocin | Mupirocin | 38 | 27 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 15 |
| Valacyclovir | Valacyclovir Hcl | 35 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | 13 |
| Donepezil Hcl | Donepezil Hcl | 33 | 13 |
| Atenolol | Atenolol | 31 | 14 |
| Buspirone Hcl | Buspirone Hcl | 31 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Diazepam | Diazepam | 31 | 12 |
| Cefdinir | Cefdinir | 30 | 28 |
| Rizatriptan | Rizatriptan Benzoate | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 23 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Finasteride | Finasteride | 29 | 15 |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Estradiol | Estradiol | 26 | 13 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 13 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 18 |
| Irbesartan | Irbesartan | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Tobramycin | Tobramycin | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 12 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $452.28 · 22 records | Lilly USA, LLC | AREXVY, Dexcom G6 Transmitter, FARXIGA, GVOKE HYPOPEN, JARDIANCE, JATENZO, Korlym, Ozempic, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, Veozah | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error